In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases. ・The ...

May 4 (Reuters) - Mirum Pharmaceuticals said on Monday its experimental drug, volixibat, met the main goal of a mid-stage study by reducing severe itching or pruritus in patients with a type of rare ...

Mirum Pharmaceuticals announced that its experimental drug, volixibat, succeeded in a mid-stage study by alleviating severe ...

Mirum Pharmaceuticals Inc. MIRM shares are up on Monday following the announcement that the primary endpoint was met in the ...

Mirum Pharmaceuticals is prepping for a new FDA approval application after its small molecule volixibat successfully ...

Unbearable itching, crushing fatigue and years on “standby” waiting for a liver transplant became this 43-year-old divemaster ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ...

The liver often signals distress quietly through fatigue, appetite loss, subtle body changes, and skin or digestive signs.

Cirrhosis can cause scar tissue to gradually replace healthy liver cells. In time, this can affect liver function and lead to hair, skin, and nail symptoms such as rashes and discoloration. Cirrhosis ...

Persistent foot itchiness could indicate serious health conditions including diabetes, kidney disease or liver disorders, ...